BiotechTube

Camrelizumab + Nab paclitaxel + Epirubicin + Cyclophosphamide

Phase 2UNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 31/100
31
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Triple Negative Breast Cancer

Conditions

Triple Negative Breast Cancer

Trial Timeline

May 20, 2020 → Feb 28, 2024

NCT ID
NCT04676997

About Camrelizumab + Nab paclitaxel + Epirubicin + Cyclophosphamide

Camrelizumab + Nab paclitaxel + Epirubicin + Cyclophosphamide is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Triple Negative Breast Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT04676997. Target conditions include Triple Negative Breast Cancer.

What happened to similar drugs?

1 of 20 similar drugs in Triple Negative Breast Cancer were approved

Approved (1) Terminated (1) Active (18)
✅Taxane and Carboplatin + Short-term SintilimabInnovent BiologicsApproved
🔄Camrelizumab Plus Chemotherapy + placebo+chemotherapyJiangsu Hengrui MedicinePhase 3
🔄Cyclophosphamide + Placebo + Doxorubicin + Paclitaxel + Carboplatin + Veliparib + PlaceboAbbViePhase 3
🔄Capivasertib + Paclitaxel + PlaceboAstraZenecaPhase 3
🔄Sacituzumab Govitecan-hziy + Pembrolizumab + Paclitaxel + nab-Paclitaxel + Gemcitabine + CarboplatinMerckPhase 3
🔄Pembrolizumab + Sacituzumab tirumotecan + CapecitabineMerckPhase 3
🔄pembrolizumab + capecitabine + eribulin + gemcitabine + vinorelbineMerckPhase 3

Hype Score Breakdown

Clinical
12
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04676997Phase 2UNKNOWN

Competing Products

20 competing products in Triple Negative Breast Cancer

See all competitors
ProductCompanyStageHype Score
BBI-355 + Erlotinib + Futibatinib + BBI-825Boundless BioPhase 1
23
eFT508eFFECTOR TherapeuticsPhase 2
17
No drugDaiichi SankyoPre-clinical
30
Tivozanib Hydrochloride + paclitaxel + PlaceboAstellas PharmaPhase 2
27
EnzalutamideAstellas PharmaPhase 2
35
Abemaciclib + BicalutamideEli LillyPhase 2
42
Camrelizumab + Apatinib + Nab-paclitaxel + Epirubicin + CyclophosphamideJiangsu Hengrui MedicinePhase 2
42
Camrelizumab Plus Chemotherapy + placebo+chemotherapyJiangsu Hengrui MedicinePhase 3
40
Camrelizumab + Nab-Paclitaxel + CarboplatinJiangsu Hengrui MedicinePhase 2/3
34
Fluzoparib+Paclitaxel + Epirubicin+CyclophosphamideJiangsu Hengrui MedicinePhase 2
42
SHR-1210 + Apatinib +FluzoparibJiangsu Hengrui MedicinePhase 1
29
Cyclophosphamide + Placebo + Doxorubicin + Paclitaxel + Carboplatin + Veliparib + PlaceboAbbViePhase 3
40
Combination of Veliparib + LapatinibAbbViePre-clinical
26
Capivasertib + ItraconazoleAstraZenecaPhase 1
29
Datopotamab Deruxtecan (Dato-DXd) + DurvalumabAstraZenecaPhase 2
42
Paclitaxel + Carboplatin + MEDI4736 + MEDI9447AstraZenecaPhase 1/2
36
KU-0059436 (AZD2281)(PARP inhibitor) + Carboplatin + KU-0059436 (AZD2281)(PARP inhibitor) + Paclitaxel + KU-0059436 (AZD2281)(PARP inhibitor) + Paclitaxel + CarboplatinAstraZenecaPhase 1
29
Capivasertib + Paclitaxel + PlaceboAstraZenecaPhase 3
44
Olaparib Oral Product + Olaparib Oral Product in combination with DurvalumabAstraZenecaPhase 2
35
Durvalumab + Capivasertib + Oleclumab + Paclitaxel + Trastuzumab deruxtecan + Datopotamab deruxtecanAstraZenecaPhase 1/2
36